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ABSTRACT 
Objective: Bougainvillea is a natural source with potential for clinical use, and this plant is routinely employed in traditional Medicine in Mexico. 
This study planned to evaluate the effect of ethanolic extract partitioned of Bougainvillea x buttiana on acute and chronic inflammation.  
Methods: The extract from Bougainvillea x buttiana partitioned originated two phases the aqueous (BxbREaq) and organic (BxbREop) phases were 
employed in anti-inflammatory activity. Acute inflammation was evaluated using the carrageenan model, whereas the chronic inflammation with 
anti-arthritic potential was explored with complete Freund´s adjuvant (CFA). Arthritis was caused by intradermal inoculation of CFA, and the 
extract was administered orally at different doses for 21 d. Paw oedema was determined at 7, 14 and 21 d, and serum from the mice were obtained 
to detect cytokine levels by ELISA and for biological assays.  
Results: Phytochemistry studies revealed that these extracts contain alkaloids, carbohydrates, fatty acids, and tannins. The results demonstrated 
that these extracts significantly inhibited mouse paw oedema for acute and chronic inflammation in a dose-dependent manner. Additionally, 
BxbREop extracts markedly inhibited the production of TNF-α, IL-1β, and IL-6 and remarkably increased IL-10 in serum from mice with control or 
arthritic groups.  
Conclusion: The combined results suggest that BxbREop extract shows a potent effect in mice against CFA-induced arthritis for its ability to inhibit 
paw oedema and arthritic symptoms. 
Keywords: Arthritis, Complete Freund´s adjuvant, Anti-arthritis activity. 




Rheumatoid arthritis (RA) is described as a chronic inflammatory 
systemic autoimmune disease characterized by progressive cartilage 
degradation with synovial inflammation, proliferation on the 
synovial linings and irreversible joint damage, and it can alter 
another body parts [1-4]. RA can cause joint destruction and the 
aggressive cartilage destruction, progressive bone erosions, 
swelling, difficulty moving, pain and elevated pro-inflammatory 
mediator’s production [3, 4].  
The drug therapies for rheumatism include a) steroids, b) non-
steroidal anti-inflammatory drugs (NSAIDs), c) disease-modifying 
anti-rheumatic drugs (DMARDS) and d) immunosuppressive drugs. 
Unfortunately, although these drugs have been shown to improve 
the signs and symptoms, alter the natural history of the disease and 
improve the quality of life of patients, until now there is still no cure. 
These available therapies are associated with strong side effects [5-
8]. The action mechanisms of these drugs are incompletely 
understood; they reduce joint swelling and pain, decrease acute 
phase markers, limit the progressive damage of joint, and improve 
function. The agents for the RA treatment, include the use of 
interleukin inhibitors, T cell co-stimulatory blockers, and B cell 
depletion molecules. Different pro-inflammatory mediators, such as 
reactive oxygen species, prostaglandins, leukotriene’s and cytokines 
released by macrophages contribute to RA [9, 10]. For the treatment 
of chronic inflammation, it may be by regulating these mediators 
secreted by immune cells or by inhibiting enzymes such as 
cyclooxygenase and lipoxygenase [11, 12]. Currently, the objective of 
RA treatments is to reduce joint inflammation and pain, maximize 
joint function, and prevent joint destruction and deformity. The 
rheumatoid joint includes distinct pro-inflammatory cytokines like 
interleukin-1 (IL-1), IL-6, IL-8, IL-15, IL-16, IL-17, IL-18, IL-23, 
tumor necrosis factor-alpha (TNF-α), granulocyte macrophage-
colony stimulating factor, and monocyte chemoattractant protein-1. 
Regarding anti-inflammatory cytokines, they include IL-4, IL-10, IL-
11, IL-13, and IL-18 [13]. The imbalance between pro-and anti-
inflammatory cytokines, and during RA it causes joint destruction and 
the angiogenesis in the synovial membrane can contribute to disease 
progression, as can the production of inflammatory cells that infiltrate 
and destroy synovial tissue [14-17]. Pro-inflammatory cytokines such 
as IL-1β and TNF-α are the targets of the strategies used for to the 
treatment to decrease the signs and symptoms of RA without causing 
adverse effects [18-22]. There are distinct plants including 
Bougainvillea that has shown ability to reduce chronic inflammation of 
joints as is the case with RA and osteoarthritis [21-28].  
This investigation was designed to check the effect of partitioned 
Bougainvillea x buttiana extract using an animal model of RA and 
assess the effect of the extract on pro-inflammatory cytokines by 
examining the TNF-α, IL-1β, and IL-6 levels.  
MATERIALS AND METHODS 
Chemicals and reagents 
RPMI-1640 medium, dimethylformamide, fetal bovine serum (FBS), 
ethanol, and 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) 
(ABTS) were purchased from Sigma Aldrich Chemical Co. (Toluca, 
Mexico). The monoclonal antibodies used in this assay were anti-
mouse capture and biotin-labeled detection and the respective 
interleukins recombinants were obtained from DB Biosciences 
Pharmingen (EUA). All other reagents and solvents are of analytical 
grade. 
Collection and identification of plant material  
The plant material for Bougainvillea x buttiana was procured from 
Cuernavaca, Morelos, identified with the foil: 33870 in the 
Herbarium HUMO, CIByC (UAEM).  
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Preparation of extract 
The whole plant material was cleaned, cut into small pieces, and shade 
dried. The plant material was pulverized in powder and extracted with 
ethanol by Soxhlet extraction. The solvent was evaporated in a rotary 
evaporator at 40-45 °C, and the extract obtained was kept on 
refrigeration at 4 °C. This ethanolic extract (BxbRE) was submitted to 
the bipartition process described in detailed in the patent application 
(IMPI 10033981514 28/12/2017). In brief, water 200 ml and ethyl 
acetate 100 ml (ratio of 2: 1). The extract was stirred vigorously for 1 h 
until dissolved in the immiscible solvent system. After agitation, the 
system was left to rest until a partitioned portion was obtained in the 
extract, obtaining two phases, the aqueous and organic phases 
BxbREaq and BxbREop, respectively. Each partitioned phase was 
separated, concentrated and reduced pressure in a rotary evaporator, 
and kept under refrigeration at 4 °C. Both phases were assayed with 
respect to the acute inflammation.  
Qualitative phytochemical analysis 
Phytochemical screening to detect the compounds in each phase purified 
and dried from an extract of B. x buttiana was performed by use of 
standard methods to identify different constituents including Wagner´s 
test for detecting alkaloids, Fehling´s test for carbohydrates, colorimetric 
method for fatty acids, and ferric chloride test for tannins [28]. 
Animals 
BALB/c female mice with (15–20 g) were used for the anti-
inflammatory study. The animals were maintained under basic 
laboratory conditions, feed and water were administered ad libitum. 
All experimental protocols were submitted and authorized by the 
Committee (CCUAL-FM-UAEM) with registration number 002/2016.  
Acute inflammation with use of carrageenan-induced paw oedema 
An oedema model was carried out with the carrageenan-induced 
paw being utilized to assess the acute anti-inflammatory potential 
[29]. Experimental animals were randomly separated within 
different groups of six animals. Before treatment, the volume of the 
right hind paw of each animal was measured by plethysmometer as 
the initial paw volume (V0). Control group was injected with 0.9% 
saline, or standard drug (Indomethacin at 10 mg/kg) or BxbREaq or 
BxbREop extracts (at 40 mg/kg) was given orally to the animals. 
Thirty minutes after injection of different treatments, each mouse 
received 1% carrageenan in its right hind paw, and its volume 
oedema was evaluated at 1st, 2nd, 3rd, 4th, 5th and 6th h after 
carrageenan injection (Vt). The percent inhibition in oedema volume 
was obtained by the formula:  
% inhibition of oedema = 1- vt-v0 treated
vt-v0 control
 x 100 
Acute toxicity studies 
Groups of animals 15–20 g maintained under basic laboratory 
conditions were used for toxicity testing as described by OECD–
Guideline number 425 [30]. Groups of 6 mice were orally treated 
with aqueous and organic phases purified and dried from B. x 
buttiana extracts at one of four doses (5, 50, 500 and 2000 mg/kg). 
Animals were individually observed for the control of toxic 
symptoms such as locomotion, convulsions, and mortality for 72 h. 
All the observations of the different parameters were systematically 
recorded and maintained for each mouse individually. In mice 
injected with 500 and 2000 mg/kg remained under observation for 
14 d for additional toxicity study. 
Adjuvant-induced chronic arthritis 
The intradermal injection of dead mycobacteria (M. tuberculosis) 
suspended in liquid paraffin oil to make 5 mg/ml (of Freund’s 
adjuvant) in mice induced arthritis in the articulations in genetically 
predisposed animals [31]. Animals randomly selected weighing 15-
20 g were separated into seven different groups of 6 animals. Table 
1 shows the treatment schedule. 
 
Table 1: Schedule of treatment 
Group Treatment 
1 Normal control (saline solution) 
2 Complete Freund´s adjuvant (arthritic control) 
3 Complete Freund´s adjuvant+Indomethacin (10 mg/kg) 
4 Complete Freund´s adjuvant+BxbREop 0.04 mg/mice 
5 Complete Freund´s adjuvant+BxbREop 0.4 mg/mice 
6 Complete Freund´s adjuvant+BxbREop 4 mg/mice 
7 Complete Freund´s adjuvant+BxbREop 40 mg/mice 
 
Dosing was started on day 1, 120 min before mouse immunization 
with heat-killed M. tuberculosis (10 mg/2 ml) in complete Freund´s 
adjuvant (CFA). The immunization dose used of 50 µl in the subplantar 
region of the right hind paw, and it was continued once a day for 21 d. 
The volume of both hind paws was assessed with volume differential 
after 0, 7, 14, and 21 d with the volume of the left paw taken as 
uninfected paw volume. Percent inhibition was calculated by the 
difference between right and left paw oedema by the formula:  
% inhibition = 1- T
C
 x 100 
Where C = mean oedema in control group and T = oedema in the 
treated group.  
Adjuvant-induced chronic arthritis 
Animals injected as above described at the end of 0, 7th, 14th, and 21st 
day were anesthetized and the blood was collected from the retro-
orbital plexus. The serum was separated from the rest of the blood 
using a high-speed centrifuge at 3500 rpm for 20 min and 
maintained at-20 °C until cytokine determinations. 
Measurement of cytokines 
The TNF presence was investigated using the standard assay with 
L929 cells [32]. The production of IL-1β, IL-6, and IL-10 was 
determined using ELISA in accordance with the manufacturer's 
instructions from DB Biosciences Pharmingen (EUA) [33]. 
Statistical analysis 
Data were expressed as the mean±SD (n = 6). The repeated measure 
analysis of variance (ANOVA) followed Bonferroni´s test or Student´s 
t-test for independent samples. P values less than 0.05 (P<0.05) 
were considered significant.  
RESULTS AND DISCUSSION 
The anti-inflammatory drugs usually prescribed for the treatment of 
chronic inflammatory diseases, such as rheumatoid arthritis, are 
prescribed in the long run for proper control of the immune system. 
Therefore, it is a great need to develop secure and valid drugs for 
long-term use. Many investigations have demonstrated molecules 
collected from natural sources for the establishment of new 
treatments for clinical use [34]. In this study for studies of acute 
toxicity the mice were treated with 2000 mg/kg of BxbREop or 
BxbREaq did not show mortality or physical changes in skin, eyes, 
nasal respiratory rate, circulatory signs or autonomic effects. Since 
none of the described toxic signs or symptoms or mortality was 
observed in the animals at the above-mentioned dose, 0.04 up to 40 
mg/kg body weight of extract were selected for evaluation of anti-
inflammatory activity (data not shown). 
The phytochemical qualitative analysis of both partitioned ethanolic 
extracts contains alkaloids, carbohydrates, fatty acids and tannins 
(table 2). 
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Table 2: Phytochemical screening of ethanolic extract 
Phytochemical test for Results 
BxbREop BxbREaq 
Alkaloids +++ ++ 
Carbohydrates +++ ++ 
Fatty acids +++ + 
Tannins ++ + 
Absent (−), present (+), moderate (++), and abundant (+++) 
 
In different extracts, the major secondary metabolites in plants are the 
alkaloids and tannins with pronounced pharmacological activities [35, 
36]. In BxbREop extract shows the different active constituents. 
Another component group present in plants is the phenolics, which 
include phenolic acids and tannins that possesses activities, such as 
anti-mutagenic, antimicrobial, antioxidant and anti-inflammatory [35-
37]. Others bioactive agents present in medicinal plants belong to 
secondary metabolites such as terpenoids or flavonoids in nature are 
known to possess anti-inflammatory properties [35-37]. The increased 
activity with increased concentration may be because of the higher 
concentration of bioactive agents in different extracts. 
For the study of acute inflammation mice, carrageenan paw oedema 
and mycobacterium-induced adjuvant arthritis of chronic 
inflammation are the model most used to detect the anti-
inflammatory effects of many natural products [24]. The effect of the 
partitioned ethanolic extract on acute inflammatory was determined 
by the carrageenan-induced hind paw oedema model. We compared 
acute inflammation in animals orally injected with the aqueous 
phase and an organic phase (fig. 1). For all animals injected with 
BxbREop extract, the paw oedema volume was significantly smaller 
when compared to that observed in the control groups and BxbREaq 
extract (P<0.001). In groups injected with indomethacin, the paw 
oedema volume was similar that obtained for animals injected with 
BxbREop extract at 40 mg/kg. The anti-edematogenic response 
appeared in a dose-dependent manner (fig. 1). 
In this study, the BxbREop extract was analyzed for changes in 
activity with dose variation, it was observed that the increased doses 
showed increased anti-inflammatory activity. For animal groups 
injected with BxbREop extract the mean of inhibition percentage was 
38.33%, 48.33%, 55.26% and 60.50% for 0.04, 0.4, 4 and 40 mg/kg, 
respectively. In indomethacin groups, the mean of inhibition percent 
was 69.41% (table 3). 
 
 
Fig. 1: Effect of BxbREaq and/or BxbReop extracts on carrageenan-induced hind paw oedema in mice, the animals were treated as above 
described. In the charts each point represents mean±SD. (n=6) * P<0.001 
 
Table 3: Percentage inhibition of carrageenan-induced mice paw edema by BxbREop extract 
Treatment Time (h) Mean of inhibition % 
1 2 3 4 5 6 
Indomethacin 50 53 76 78.5 79 80 69.41 


































According to the results obtained in the acute inflammation assays, the 
BxbREop extract showed high effectiveness. The effect of BxbREop 
extract on chronic inflammation was determined using the adjuvant-
induced arthritis model. The paw volume was measured for twenty-one 
days. In animal groups treated with BxbREop extract, a decrease was 
observed when compared to arthritic controls. Uninjected paws showed 
oedema formation at 7 d after mycobacteria immunization. However, the 
oedema volume in animals injected with BxbREop extracts lower than 
those obtained in arthritic controls. Overall, in treated groups, the 
inhibition of oedema was dose-dependent manner (fig. 2). The results 
obtained were found to be significant compared to arthritic controls at 
P<0.01. A similar reduction of paw volume was obtained after the 
treatment with indomethacin and/or BxbREop extract. For all mouse 
groups injected with different amounts of extract and/or indomethacin, 
the paw volume on the 21st day was significantly lower than those 
obtained in the control group (P<0.01). 
  
Petricevich et al. 
Int J Pharm Pharm Sci, Vol 10, Issue 3, 117-123 
120 
 
Fig. 2: Paw oedema female BALB/c mice weighing between 15–20 g were grouped and treated as above described. In the charts each point 
represents the results (mean±SD) from 6 mice. (n=6) * P<0.01 
 
The paw oedema inhibition is shown in fig. 3. For the animal groups 
treated with 40 mg/kg of BxbREop extract, the percent inhibition 
was 17, 48 and 53% at 7, 14 and 21 d, respectively. In the group of 
animals treated with indomethacin, the mean percent inhibition was 
15, 41 and 47% at 7, 14 and 21 d, respectively (fig. 3). The mean 
percent inhibition obtained in groups of animals treated with 




Fig. 3: Paw oedema inhibition percent, female BALB/c mice weighing 15–20 g were grouped and treated as above described. In the charts, 
each point represents the results (mean±SD) from 6 mice 
 
The BxbREop extract has shown a more pronounced effect compared to 
indomethacin, which indicates the inhibition of chemical mediators of 
inflammation. In case of adjuvant arthritis, the immune response to 
mycobacterial antigens has been detected and is involved in the arthritis 
development [38]. In this study, to verify that the BxbREop extract has 
anti-arthritic activity, the observations in the interleukin production was 
recorded after the injection of CFA. All doses of BxbREop extract, 0.04, 
0.4, 4 and 4 mg/kg, reduced the production of TNF-α (fig. 4). The 
production of TNF-α in the groups treated with BxbREop extract was 
significantly lower than those obtained in control group (P<0.01). In 
groups of mice treated with 40 mg/kg BxbREop extract and 
indomethacin, the TNF-α levels were decreased to 75% on the 21st d. 
 
 
Fig. 4: TNF-α levels in serum from mice, female BALB/c mice weighing 15–20 g were grouped and treated as above described. In the 
charts, each bar represents the results (mean±SD) from 6 mice. *P<0.01 
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All doses of BxbREop, 0.04, 0.4, 4 and 40 mg/kg also were capable 
to reduce the IL-6 levels. In groups injected with BxbREop extract 
the levels of IL-6 were significantly lower when compared to the 
control group (P<0.01). In groups of mice treated with 40 mg/kg 
BxbREop extract the IL-6 levels were significantly decreased to 
75% on the 7th, 14th and 21st d (P<0.001). In the same periods in 
groups treated with indomethacin, the IL-6 production was 
reduced to 67% (fig. 5). 
  
 
Fig. 5: IL-6 levels in serum from mice, female BALB/c mice weighing 15–20 g were grouped and treated as above described. In the charts 
each bar represents the results (mean±SD) from 6 mice, *P<0.01 and **P<0.001 
 
In all groups of animals injected with BxbREop extract the IL-1β 
production was reduced (fig. 6). In these groups, the levels of IL-1β 
were significantly lower when compared to the control group 
(P<0.01). In groups of mice treated with 40 mg/kg BxbREop extract 
the IL-1β levels were significantly decreased to 75% on the 7th, 14th 
and 21st day (P<0.001). Similar results were observed in animals 
injected with indomethacin. 
In contrast, the levels of IL-10 in groups of animals treated with 0.04, 
0.4, 4 and 4 mg/kg of BxbREop extract were increased (fig. 7). Groups 
of animals injected with BxbREop the IL-10 levels were significantly 
higher than those observed for the control group (P<0.01). The 
maximum production of IL-10 was obtained in groups of mice injected 
with 40 mg/kg BxbREop extract on the 21st day. Similar results were 
observed in groups injected with indomethacin (fig. 7). 
  
 
Fig. 6: IL-1β levels in serum from mice, female BALB/c mice weighing 15–20 g were grouped and treated as above described. In the charts 
each bar represents the results (mean±SD) from 6 mice, *P<0.01 and **P<0.001 
 
 
Fig. 7: IL-10 levels in serum from mice, female BALB/c mice weighing 15–20 g were grouped and treated as above described. Each bar 
represents the results (mean±SD) from 6 mice. *P<0.01 and **P<0.001 
 
The T-cell mediated responses [39, 40] and the cross-reactivity to 
purified cartilage proteoglycans [41] included in RA [42]. Since RA 
involves the inflamed joints, the model of adjuvant arthritis model 
presented similar symptoms. Previously we showed the 
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immunomodulatory activity of ethanolic extract [43]. The present 
study results showed that the BxbREop extract-treated arthritic 
animals decreased inflammation of joints. The reduction in paw 
oedema observed was persistent with the increment of concentration. 
In this study also found the minor development of arthritis in extract-
treated animals. In control group, the highest inflammation was found 
after 14 d, while in the extract-treated and standard groups the 
inflammation found was dramatically lower. Our results showed that 
BxbREop extract has anti-inflammatory efficacy in both acute and 
chronic inflammation. This effect of BxbREop extract may be by reason 
of the decrement of the pro-inflammatory cells [43].  
The use of non-steroidal anti-inflammatory drugs cannot block the 
development and progress of rheumatoid arthritis [44], and the 
disease-modifying antirheumatic drugs have been impeded by their 
potential of long-term, side effects, toxicity and immunosuppression 
[45]. The present study is concerned with the evaluation of the 
efficacy of BxbREop extract as anti-arthritic factors using the 
adjuvant-induced arthritis model. The present study demonstrated 
that a single injection of CFA at the plantar surface of mice 
developed pronounced arthritis in the paws, with 100% incidence. 
These results agree with the other observation Gonzalez-Gay, et al. 
2005 [46], who stated that RA is caused by a number of 
inflammatory mediators released by macrophages. Other 
investigation reported that characteristics feature of arthritic joints 
is the persistence of pro-inflammatory cytokines such as TNF-α and 
IL-1 produced by the inflamed synovium [47]. With respect to TNF-α 
is considered as an important factor in promoting mechanisms 
leading to inflammation, whereas IL-1 led to cartilage and bone 
destruction. In this study, we found that BxbREop extract 
significantly inhibited the levels of three important pro-
inflammatory mediators, IL-1, IL-6 and TNF-α, and increased levels 
of IL-10 in mice. Our results indicated that the BxbREop extract 
exhibits anti-inflammatory properties in arthritic mice. The results 
of the present study are a coincidence with previous studies that 
have reported similar observations [48, 49]. 
CONCLUSION 
Our results contribute to the continued research of this extract for 
the treatment of arthritis. However, no animal model completely 
depicts the pathophysiology and disease progression in this 
debilitating disease. Therefore, further research studies will be 
needed to elucidate the exact mechanism of this extract. From the 
results obtained, suggest the potential effect of BxbREop extract as 
an anti-arthritic agent towards CFA-induced arthritis in mice.  
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